Timothy Eugene Sullivan - 05 Jun 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
05 Jun 2023
Net transactions value
-$5,496,643
Form type
4
Filing time
06 Jun 2023, 16:59:30 UTC
Previous filing
03 May 2023
Next filing
06 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $699,883 +69,779 +90% $10.03 147,492 05 Jun 2023 Direct F2
transaction APLS Common Stock Sale $144,967 -1,600 -1.1% $90.60 145,892 05 Jun 2023 Direct F2, F3
transaction APLS Common Stock Sale $2,687,121 -30,609 -21% $87.79 115,283 05 Jun 2023 Direct F2, F4
transaction APLS Common Stock Sale $624,210 -7,064 -6.1% $88.36 108,219 05 Jun 2023 Direct F2, F5
transaction APLS Common Stock Sale $2,740,229 -30,506 -28% $89.83 77,713 05 Jun 2023 Direct F2, F6
holding APLS Common Stock 56,232 05 Jun 2023 The Timothy E Sullivan Irrevocable Trust of 2023 F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -69,779 -19% $0.000000 288,840 05 Jun 2023 Common Stock 69,779 $10.03 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F2 This is a scheduled exercise & sale from 10b5-1 trading plan.
F3 This transaction was executed in multiple trades at prices ranging from $90.380 - $90.790. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $87.155 - $88.150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $88.160 - $89.130. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $89.375 - $90.370. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This option was granted on October 18, 2017 and fully vested.